Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.05 | 0.05 | -0.74 |
| FCF Yield | 39.60% | -0.62% | -13.42% | -1.43% |
| EV / EBITDA | 5.27 | -29.44 | 8.40 | 22.82 |
| Quality | ||||
| ROIC | 4.12% | -4.62% | 3.70% | 1.47% |
| Gross Margin | 33.26% | 17.35% | 32.61% | 31.94% |
| Cash Conversion Ratio | 3.51 | -0.50 | -1.06 | -0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.65% | -5.07% | 10.32% | 11.24% |
| Free Cash Flow Growth | 4,367.63% | 95.23% | -388.32% | -14.43% |
| Safety | ||||
| Net Debt / EBITDA | 1.08 | -6.02 | 3.13 | 3.71 |
| Interest Coverage | 5.25 | -3.86 | 3.52 | 1.13 |
| Efficiency | ||||
| Inventory Turnover | 0.65 | 0.68 | 0.71 | 0.92 |
| Cash Conversion Cycle | 615.88 | 600.56 | 568.28 | 452.63 |